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Gains of chromosomes 7p and 8q are associated with poor prognosis among oestrogen receptor-positive (ERþ) stage I/II breast
cancer. To identify transcriptional changes associated with this breast cancer subtype, we applied suppression subtractive
hybridisation method to analyse differentially expressed genes among six breast tumours with and without chromosomal 7p and 8q
gains. Identified mRNAs were validated by real-time RT–PCR in tissue samples obtained from 186 patients with stage I/II breast
cancer. Advanced statistical methods were applied to identify associations of mRNA expression with distant metastasis-free survival
(DMFS). mRNA expression of the key enzyme of cholesterol biosynthesis, squalene epoxidase (SQLE, chromosomal location
8q24.1), was associated with ERþ 7pþ/8qþ breast cancer. Distant metastasis-free survival in stage I/II breast cancer cases was
significantly inversely related to SQLE mRNA in multivariate Cox analysis (Po0.001) in two independent patient cohorts of 160
patients each. The clinically favourable group associated with a low SQLE mRNA expression could be further divided by mRNA
expression levels of the oestrogen-regulated zinc transporter LIV-1. The data strongly support that SQLE mRNA expression might
indicate high-risk ERþ stage I/II breast cancers. Further studies on tumour tissue from standardised treated patients, for example with
tamoxifen, may validate the role of SQLE as a novel diagnostic parameter for ERþ early stage breast cancers.
British Journal of Cancer (2008) 99, 774–780. doi:10.1038/sj.bjc.6604556 www.bjcancer.com
Published online 12 August 2008
& 2008 Cancer Research UK
Keywords: squalene epoxidase; oestrogen receptor; LIV-1; breast cancer; 8q; 7p
                                                       
Distinct chromosomal copy number gains are common in breast
cancer and indicate distinct genetic pathways in tumorigenesis. In
systematic studies, using comparative genomic hybridisation
(CGH), chromosomal gains were observed most commonly on
chromosomes 1q (50–55%), 8q (60%), 16p (40–60%), 17q
(25–30%) and 20q (20–25%) (Rennstam et al, 2003; Fridlyand
et al, 2006; Mitelman et al, 2007). A particularly poor clinical
outcome has been associated with 8q gains (Rennstam et al,2 0 0 3 ) .
Moreover, we have previously characterised a subtype of stage I/IIa
oestrogen receptor-positive (ERþ) poorly differentiated breast carci-
nomas displaying gains of chromosome 7p. These tumours exhibit
shorter time to progression compared with other breast cancer
phenotypes and high frequency of 8q gains (Rennstam et al, 2003;
Korsching et al, 2004; Helms et al, 2005). In addition, a high proli-
feration rate combined with a low HER2, p53 and EGFR expression
and a high degree of cytogenetic instability were found among these
tumours. A more precise definition of these patients might determine
which of these ERþ node-negative breast cancer patients would
benefit from additional treatment besides endocrine therapy.
Recent studies have provided solid evidence that tumour gene
expression profiles can provide useful prognostic information for
patients with both node-negative and node-positive breast cancer
(O’Shaughnessy, 2006; Massague, 2007; Mook et al, 2007).
Therefore, to identify novel markers useful for gene expression-
based patient prognosis, we compared mRNA expression of breast
cancer cases displaying gains of 7p and 8q with cases showing no
aberrations on chromosomes 7p and 8q by suppression subtractive
hybridisation PCR (SSH). Differential expression of 60 gene
products identified by SSH was first validated by real-time
RT–PCR using the original sample set. A correlation analysis
between 12 validated differentially regulated genes and (i) clinical
parameters and (ii) established molecular parameters (i.e. ER,
EGFR, HER2, p53 and Bcl2) on a cohort of 160 stage I/II patients
with full clinical records and long-term follow-up was performed
to assess prognostic relevance.
Using the exploratory approach of recursive partitioning and
regression tree analysis, squalene epoxidase (SQLE) was identified
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sas the most significant parameter to cluster patients by outcome.
An additional impact was shown for the ER-related gene LIV-1 by
further splitting the SQLE-low subgroup of patients. These results
held true in multivariate Cox analysis when compared to
established risk factors in stage I/II breast cancer.
MATERIALS AND METHODS
Suppression subtractive hybridisation
The study protocol for the storage, processing and analysis of
patient material was approved by the local ethics committee.
Suppression subtractive hybridisation expression analysis was
performed on six ductal invasive grade 2 and 3 breast cancer
cases with very similar protein expression pattern (ER-positive,
PR-positive, erbB2 0–2, Dako-Score/no-erbB2-amplification,
EGFR-negative, p53 0–1, Ck 5-negative, Ck 8/18-positive) and
cytogenetic background except for 7p and 8q (all tumours
displayed a loss of chromosome 16q), which has been previously
described in more detail (Korsching et al, 2004). Three of the six
tumours harboured a gain on chromosome 7p and 8q (designated
as ‘gain 7/8’) as opposed to three cases without these cytogenetic
changes (norm 7/8).
The gain 7/8 tumours displayed more than 20% Mib-1 staining
and more than 12 genetic alterations on average per case as
revealed by CGH analysis. In contrast, norm 7/8 tumours exhibited
only 5–10% Mib-1 staining and 5.3 genetic alterations on average
per case.
Five 10-mm sections of morphological homogenous tumour
areas were pooled from fresh frozen tissue and total RNA was
isolated by StrataPrep total RNA Microprep Kit (Stratagene,
Amsterdam, The Netherlands) including DNase digestion. cDNA
was synthesised and amplified to about 3mg cDNA starting from
100ng total RNA derived from each sample with the SMART PCR
cDNA Synthesis Kit (BD Clontech, Heidelberg, Germany).
Suppression subtractive hybridisation was performed with the
PCR-Select cDNA Subtraction Kit (BD Clontech). To equalise the
cytogenetic background, cDNA from three specimens were pooled
for each group and analysed by SSH in forward and reverse
directions.
Creation of a subtracted cDNA library
Freshly prepared 10 cycle secondary SSH-PCRs resulting from the
forward and the reverse subtractions, respectively, were cloned
into the pCR 2.1. vector using the Original T/A Cloning Kit
(Invitrogen, Karlsruhe, Germany) and transformed to Escherichia
coli TOP 10 F’ according to the manufacturer’s instructions.
Sequencing of subtracted cDNA library
One hundred and ninety-two bacterial clones resulting from each
of the subtractions were picked and cultured in 15 ml TB medium
in deep-well plates at 371C overnight. Plasmids were isolated using
the Wizard Magnesil Plasmid Purification System (Promega,
Mannheim, Germany) and the inserts sequenced with a M13
forward Promotor ( 21) primer (50-TGTAAAACGACGGCCAGT-30)
using standard techniques. The sequences of the inserts of
differentially expressed genes were identified using NCBI Blast
search (blastn)(Altschul et al, 1997).
Relative expression quantification of SSH hits by real-time
RT–PCR
Expression of 60 of the genes identified as differentially expressed
by SSH was quantified in all the six tumour specimens by SYBR
Green real-time RT–PCR. For this purpose, DNase-treated total
RNA derived from the six tumours was reverse transcribed using
Multiscribe Reverse Transcriptase and random hexamers (Applied
Biosystems, Foster City, CA, USA) according to the manufacturer’s
instructions. Quantitative PCR analyses were performed on an ABI
7900 Sequence Detection System (Applied Biosystems) in duplexes
using the Quantitect SYBR Green PCR kit (Qiagen, Hilden,
Germany) and normalised to 18S rRNA (Pre-Developed TaqMan
Assay Reagents Control Kit; Applied Biosystems). Primer design
was performed with the help of the ‘Primer Express’ software
(Applied Biosystems). To prevent the amplification of genomic
sequences, at least one primer of each pair was designed spanning
two exons. Specificity of amplification was checked by melting
curve analysis. Primer oligonucleotides were purchased from
Operon (Cologne, Germany). PCR conditions were: initial denatu-
ration for 10min at 951C followed by 50 cycles consisting of 15s at
951C and 1min at 601C. Expression ratios between two samples
were calculated from differences in threshold cycles at which an
exponential increase in reporter fluorescence could first be detec-
ted (CT values). Results of duplicate experiments were averaged.
Real-time RT–PCR profiling on large breast cancer sample
set
In addition to the six samples used for SSH, a fresh frozen breast
tumour sample set accrued from 1986 to 1998 at the University
Medical Centre Muenster served as the source of samples for
the prognostic evaluation of differentially expressed genes. The
inclusion criteria for the primary study included: T1 or T2
tumours, lymph node-negative (determined by full axillary
lymph node dissection) and follow-up for 5 years. 186 patients
had known recurrence status at the last follow-up. A subset of 160
patients (of 186) was evaluable for clinical follow-up that has been
classified for ER, PR, HER2 and therapy. We chose distant
metastasis-free survival (DMFS) as the primary end point because
it is most directly linked to cancer-related death and cancer cell
motility.
Sample processing
Total RNA was isolated from 50 to 100mg of frozen breast cancer
tissues using RNeasy Mini kit (Qiagen, Valencia, CA, USA). To
ensure absence of DNA contamination, an on-column DNase I
treatment was performed. Total RNA was quantified using
spectrophotometer OD260 measurements. The amplifiable RNA
was determined by measuring the expression level of a house-
keeping gene (EEF1A1).
Gene expression profiling
One-step RT–PCR with SYBR
s Green was used for gene
expression profiling as published previously (Rogge et al, 2000).
Pre-developed and validated PCR primers (Applied Biosystems)
were used to amplify all known splice variants. Fifteen-microlitre
reactions were performed in duplicates using amplification plates
in 384-well format. The cycle profile consists of 501C 2min,
951C 1min, 601C 30min, followed by 45 cycles of 951C 15s and
601C 30s ending with dissociation analysis. Together with three
normalisation genes, the expression levels of a total of 59 targets
in 186 RNA samples were profiled. The expression level of
each gene was normalised with the average of expression levels
of three housekeeping genes (NUP214, PPIG and SLU7). The
normalised expression levels of 59 mRNAs were used for statistical
analyses.
Statistical analysis
Distant metastasis-free survival was chosen as the primary end
point of this study. Distant metastasis-free survival is defined as
the interval between the date of definitive breast cancer surgery
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sand diagnosis of first distant metastasis or the last date of follow-
up (whichever occurred first). Contralateral recurrences and
deaths without recurrence were regarded as censoring events,
whereas local recurrences were considered neither as events nor as
censoring events. The definition of DMFS end points, its events
and censoring rules were aligned with those adopted by the
National Surgical Adjuvant Breast and Bowel Project for the
prognostic molecular marker studies (Paik et al, 2004).
Disease-free survival was defined as the interval between
the date of disease diagnosis and diagnosis of the first local,
regional or distant tumour recurrence, patient death or date of last
follow-up. Overall survival (OS) was calculated as the interval
between disease diagnosis and patient death (regardless of the
cause).
Regression trees were built through an iterative process called
binary recursive partitioning, which comprises the splitting of the
data into partitions and further splitting of the branches to
minimise the squared deviations. Kaplan–Meier survival estimates
were generated and compared with the log-rank test. Multivariate
analysis was performed using Cox proportional hazards regression
model. Level of significance was P¼0.05. Cox proportional
hazards regression models have been computed using the Efron
approximation from the ‘survival’ package within the statistical
data analysis environment R version 2.5.0 (R Development Core
Team, 2007).
Analysis of microarray data
The publicly available data set of Loi et al (2007) was used
for correlation analyses of SQLE expression and survival. The
cel files (GEO accession no. GSE6532) were downloaded from
the NCBI GEO Database (www.ncbi.nlm.nih.gov/projects/geo/),
and HGU133A arrays from ERþ, N0 and T1–T2 tumours were
selected. The files were extracted and normalised using the
gcrma package (Wu et al, 2004) for R. Three probe sets were
found for SQLE (209218_at. 213562_s_at, 213577_at). The probe
set 213562_s_at was omitted as probe sets carrying the suffix _s_at
are designed to recognise multiple transcripts. To have a common
scale for the remaining two probe sets, each value was divided by
the median value of the corresponding probe set. Afterwards, the
mean of the two ratios was used to classify the samples into three
equally sized groups with respect to their SQLE expression.
Kaplan–Meier survival curves and survival statistics were
generated using the survival package for R.
RESULTS
The SSH-PCR approach yielded 135 mRNA species as putatively
upregulated and 131 genes as putatively downregulated in gain
7/8 tumours compared to norm 7/8 tumours (Supplementary
data). Of these, 60 genes were selected for validation by
quantitative RT–PCR analysis by the criterion that functional
and structural data were available. Sixteen gene products shown in
Table 1 were confirmed to be differentially regulated in at least
two of the gain 7/8 tumours compared to norm 7/8 tumours. The
difference between the average expression values for gain 7/8 cases
and norm 7/8 cases was more than 2.5-fold for these 16 gene
products. Figure 1 shows the RT–PCR data for the 12 upregulated
genes.
Expression of SQLE, constituent of gain 7/8 tumour gene
profile, predicts decreased 5-year DMFS in stage I/II breast
cancer patients
To estimate the clinical relevance of these gene products associated
with gain 7/8 tumours, their mRNA expression as well as that of
established molecular markers (i.e. HER2, EGFR, p53 and bcl2)
was quantified by real-time RT–PCR on samples from 160 patients
with stage I/IIA breast cancer with known clinical records and
long-term follow-up (Supplementary data). Among them, 66
developed distant metastases with a mean follow-up time of 27
months. The mean (s.d.) age of patients was 58 years (13 years),
with 68.7% older than 55 years. Most tumours were of medium
(41% G2) and high grades (34% G3). Fifteen per cent of the
tumours were unclassified for grade.
First, we performed exploratory recursive partitioning and
regression tree analysis to estimate the predictive value of
expression of every gene with regard to 5-year DMFS (Zhang
et al, 2001). Therefore, the stage I/IIA patient cohort was
dichotomised for high vs low DMFS at more or less than 60
months, respectively. Squalene epoxidase mRNA expression levels
split at the median classified 89.3% to the less than 60 months
DMFS group and 78.3% to the more than 60 months DMFS group
accurately. Squalene epoxidase mRNA expression levels were
found to be associated with the highest predictive values of all the
genes analysed.
Squalene epoxidase mRNA was detected in all 160 tumour
tissues, with the tumour with the highest expression displaying a
290-fold higher level of SQLE mRNA than the lowest.
Table 1 List of validated genes found to be differentially regulated in gain 7/8 tumours compared to norm 7/8 tumours
Annotation of cDNA Accession no. Locus
Genes upregulated in gain 7/8 tumours
1 CXCR4: chemokine (C-X-C motif) receptor 4 NM_003467 2q21
2 EPHA3: EphA3 NM_005233 3p11.2
3 CTNNB1: catenin (cadherin-associated protein) beta 1, 88kDa NM_001904 3p21
4 SLBP: stem-loop (histone)-binding protein NM_006527 4p16.3
5 BMPR1B: bone morphogenetic protein receptor, type IB NM_001203 4q22–q24
6 ITGA1: integrin, alpha 1 NM_181501 5p11
7 CHCHD2; 16.7kDa protein (LOC51142) NM_016139 7p14.1
8 BZW1: basic leucine zipper and W2 domains 1 NM_014670 8q22.2–q23/ 2q33
9 PRKCZ (14-3-3 zeta) NM_145690 8q23.1
10 SQLE: squalene epoxidase NM_003129 8q24.1
11 DCD: dermcidin NM_053283 12q13
12 LIV-1: LIV-1 protein, oestrogen-regulated NM_012319 18q12.1
Genes downregulated in gain 7/8 tumours
13 CALM2: calmodulin 2 (phosphorylase kinase, delta) NM_001743 2p21
14 GLI3: GLI-Kruppel family member GLI3 NM_000168 7p13
15 CXCL12/cytokine SDF-1-beta NM_000609 10q11.1
16 BUB3: budding uninhibited by benzimidazoles 3 homologue NM_004725 10q26
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sIn a second step, survival analysis according to Kaplan–Meier
algorithm was performed. The survival data analysed by Kaplan–
Meier test revealed a significant association between expression
levels of SQLE mRNA and MFS (Po0.0005, Figure 2A). The 5-year
DMFS rate differed by 48% between the SQLE high-expressing and
SQLE low-expressing group of patients. The clinically favourable
group associated with a low SQLE mRNA expression could be
further divided by LIV-1 mRNA expression. In a Kaplan–Meier
analysis, those tumours with high LIV-1 expression showed up
with an extended time until metastatic relapse (5-year DMFS 91%),
whereas the small subgroup of low LIV-1-expressing tumours
(n¼11) showed a decreased 5-year DMFS (Po0.0005; Figure 2B).
The difference in MFS probability between both subgroups was
45%. The subgroup (n¼30) of the poorest outcome was indicated
by high SQLE and low LIV-1 expression (5-year MFS 16%).
Kaplan–Meier analysis of a small subgroup of 41 patients treated
with tamoxifen (5 years) and no additional radiation or
chemotherapy confirmed a significant impact of SQLE mRNA
expression on these tumours (Po0.05). The low SQLE group
(n¼30) had a 30% better estimate of DMFS than the high SQLE
group (n¼11).
Validation of prognostic value of SQLE expression in an
independent sample set
To confirm the prognostic value of SQLE mRNA, we analysed an
independent validation cohort. Our findings hold true in this
publicly available set of Affymetrix-based expression data (Loi
et al, 2007). In a cohort of 162 ERþ lymph node-negative patients,
tumours with the highest SQLE expression indicated a highly
significantly reduced DMFS compared to the low-level expressors
(Po0.001) (Figure 3).
SQLE expression levels are not correlated with tumour
size, grading, oestrogen receptor status and HER2
expression
Multiple t-testing for SQLE mRNA expression levels for compar-
ison of the subgroups T1 vs T2, G2 vs G3, ERþ vs ER  and
HER2þ vs HER2  was performed. No significant differences
between the subgroups expressing SQLE mRNA above and below
the median were revealed. On the other hand, LIV-1 mRNA
expression level was weakly positively correlated to ER status
(Po0.05) as already reported from other studies (Dressman et al,
2001), thereby confirming the validity of our sample panel.
Significant independent influence on prognosis of the
stage I and II study population for SQLE determined by
multivariate Cox analysis
To evaluate the independent prognostic value of SQLE and the
combination of SQLE and LIV-1, we performed multivariate
survival analysis using Cox proportional hazard model as shown in
Table 2. SQLE (o median vs 4 median), pT stage (pT1 vs pT2),
histological grading (G2 vs G3), ER and PR status (positive vs
negative) were entered as covariates.
Among the established clinical parameters, only tumour size
(pT) reached borderline significant predictive value (P¼0.074).
The upregulation of SQLE reached high-level statistical signifi-
cance (P¼0.0014), indicating a conceivable independent impact of
SQLE on stage I/II breast cancer prognosis. The risk for metastasis
was increased more than five-fold for patients suffering from
tumours highly expressing SQLE (Hazard ratio (HR)¼5.11;
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Figure 1 Relative expression values of the candidate gene found to
be upregulated in gain 7/8 tumours by SSH as measured by real-time
RT–PCR. Expression values of the single tumours were normalised to
expression of 18S rRNA. For each gene product, the expression values for
all six tumours were averaged and relative expression values calculated
for each tumour.
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Figure 2 (A) Kaplan–Meier cumulative survival plot for distant
metastasis-free survival demonstrating a significant relationship between
SQLE expression and DMFS (Po0.0005). The median SQLE expression
value dichotomised the patient group for good and poor prognosis. (B)
Kaplan–Meier cumulative survival plot for distant metastasis-free survival
demonstrating a significant relationship between LIV-1 levels and DMFS in
patients with SQLE expression below median (Po0.0005). The median
LIV-1 expression value dichotomised the patient group for good and poor
prognosis.
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sPo0.0014). As depicted from univariate Kaplan–Meier life table
analysis, the formation of a linear combined covariate from SQLE
and LIV-1 mRNA expression increased HR up to 10.44 (Po0.0023)
for the condition of SQLE mRNA expression above median and
LIV-1 mRNA expression below median (SQLE(þ)/LIV-1( )).
However, LIV-1 alone had no independent contribution to the
metastasis risk estimate.
DISCUSSION
Tumours with defects on chromosome 8 have been reported in the
literature as a distinct entity of breast tumours. Biological features
of these tumours reflected by unfavourable clinical/pathological
characteristics are likely to be driven by chromosome 8 (Rennstam
et al, 2003). Consequently, focused gains of the chromosomal
region 8q21–24 have been described as being significantly
associated with alterations in disease prognosis. For instance, it
has been suggested that the amplification of oncogenes on
chromosome 8q (i.e., c-MYC and EBAG9) may support tumour
progression. Besides 8q gains, Rennstam et al (2003) also report
that less frequent gains of chromosome 7p were found in the 8qþ
poor prognostic subgroup. We have previously described a
subgroup of invasive ductal ERþ grade 3 carcinomas with
chromosomal 7p gains as their cytogenetic hallmark (Korsching
et al, 2004). These coincide with 8q gains in 50% of the cases in
this unique breast cancer subgroup. However, it remains unclear
whether chromosomal 7p gains represent the underlying cause
of tumour progression or a mere secondary reflection thereof
conceivably related to 8q gains. To gain insight into the role of
these distinct cytogenetic aberrations, we compared the mRNA
expression of two groups of ERþ invasive ductal breast cancers.
One group consisted of tumours harbouring 7p and 8q gains
and the other group was without these aberrations. The gain 7/8
tumours displayed a significantly higher number of chromosomal
aberrations (mean¼12) compared with the reference group
(mean¼5) and presented with a higher Ki67 staining as a measure
of tumour cell proliferation. However, all tumours were negative
for the molecular parameters HER2, EGFR and p53, which are
commonly associated with an unfavourable prognosis (Fitzgibbons
et al, 2000).
To assess the clinical value of our observations, we analysed a
set of 160 randomly collected samples from stage I/IIA breast
tumours with long-term follow-up and complete clinical records.
Following standard guidelines, the majority of these patients would
currently be treated with systemic adjuvant therapy (i.e. cytotoxic
or endocrine) (Goldhirsch et al, 2001; National Institutes of Health
Consensus Development Panel, 2001). However, a considerable
number of patients will remain free of disease recurrence in the
absence of additional systemic therapy. Consequently, these
patients represent the subgroup of breast cancer patients most
likely benefiting from improved prognosis estimation based on
their genetic or genomic profile.
Among the patients in this study, 41% developed metastatic
disease within a median period of follow-up of 61 months. This is
higher than the assumed distant relapse rate of 30% for those
tumours that could be deferred from meta-analysis of clinical
trial results (Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG), 2005). This might cause a slight overestimation of
the prognostic performance of the single parameters presented in
this study.
Exploratory data evaluation by means of recursive partitioning
and regression tree analysis revealed SQLE to be the most relevant
parameter among the candidate genes identified by SSH to
dichotomise patients into high vs low risk of distant metastasis.
Kaplan–Meier analysis of the patient cohort demonstrated a large
difference in DMFS on a high significance level (Po0.0001). These
findings were validated by the analysis of an independent patient
cohort where high SQLE expression indicated low DMFS on a
similar significance level (Po0.001).
LIV-1 expression levels might give additional information
by subclassification of the SQLE prognostic groups as shown by
Kaplan–Meier and Cox regression analysis. Remarkably, the
prognostic value of SQLE expression even holds true for solely
tamoxifen-treated patients (Po0.05). Considering the small size of
this subgroup, it seems advisable to enroll a larger study including
standardised and randomised treated patients to further validate
these data.
To evaluate the independent prognostic value of SQLE and LIV-1,
multivariate survival analysis using Cox proportional hazard
model was applied. The upregulation of SQLE reached a high
level of statistical significance (P¼0.0014) in the multivariate
model containing pT stage, histological grading, and expression of
ER and PR as covariates. This strongly supports the assumption
that SQLE might be an independent risk factor for metastatic
relapse in stage I/II breast cancer. Importantly, HR for tumours
showing both SQLE mRNA expression above and LIV-1 mRNA
expression below the mean compared to others was as high as
10.44. This may serve as a potential rationale for a clinical trial
setting in which patients would be stratified to receive endocrine
therapy with treatment with tamoxifen or aromatase inhibitors
based on SQLE and LIV-1 expression. LIV-1 has been demon-
strated to be correlated positively with ER expression and
negatively with histological grade (Taylor et al, 2007). Corrobo-
rating the data presented here, LIV-1 has also been demonstrated
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Figure 3 Kaplan–Meier cumulative survival plot for distant metastasis-
free survival demonstrating a significant relationship between SQLE
expression and DMFS (Po0.001). Patients were divided into three groups
of equal size with patients displaying highest (3), intermediate (2) and
lowest (1) expression of SQLE, respectively.
Table 2 Multivariate analysis for DMFS in a validation set of 160 stage I/II
breast cancer patients
Univariate (n¼160) Multivariate (n¼160)
Covariate HR (95% CI) P-value HR (95% CI) P-value
pT1 vs pT2 2.18 (0.93–5.1) 0.074 2.81 (1.09–7.25) 0.033
G2 vs G3 NA NA 0.53 (0.20–1.41) 0.20
ER+ vs ER  0.75 (0.32–1.76) 0.52 1.90 (0.60–6.06) 0.28
SQLE 5.11 (1.88–13.9) 0.0014 5.72 (2.20–16.2) 0.001
LIV-1 0.49 (0.17–1.46) 0.2 0.38 (0.11–1.32) 0.13
SQLE(+)/LIV-1(+) 5.27 (1.73–16.1) 0.0035 NA NA
SQLE(+)/LIV-1( ) 10.44 (2.31–47.2) 0.0023 NA NA
CI¼confidence interval; DMFS¼distant metastasis-free survival; HR¼hazards ratio;
SQLE¼squalene epoxidase; NA¼Not applicable.
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sto predict longer relapse-free survival and OS in ERþ breast
cancer (Kasper et al, 2005). The same study indicated that the
predictive value of LIV-1 is dependent on other prognostic
markers. Our data identified SQLE to be one of these factors,
even though the functional relationship remains unclear.
Studies indicated that LIV-1 plays a role in tissue differentiation
and epithelial mesenchymal transition (Taylor et al, 2004; Zhao
et al, 2007). This biological role is in compliance with the negative
correlation of LIV-1 with histological grade. Histological grade
represents the histomorphological correlate of (breast) cancer
differentiation and predicts an unfavourable prognosis (Fukutomi
and Akashi-Tanaka, 2002; Liedtke et al, 2008).
Published data on SQLE suggest a biochemical rationale for a
protective effect in SQLE-negative tumours as observed in this
study and the prognostic and predictive implications. Distribution
studies in human tissues show a very low expression of SQLE in
non-cholesterogenic tissues (including the mammary gland)
compared with cholesterogenic tissues like the liver. It is assumed
that the reaction catalysed by SQLE is the rate limiting step in
cholesterol biosynthesis, in post-HMG CoA regulation (Astruc
et al, 1977; Tabacik et al, 1981). This is supported by the fact that
cell growth inhibited by a specific SQLE inhibitor (NB-598) could
be rescued by small amounts of cholesterol added to the culture
medium (Xu et al, 2005).
Given that SQLE resides on chromosome 8q24.1 (Nagai et al,
1997), which is commonly involved in 8q gains in breast cancer, it
seems conceivable that tumour-promoting or -initiating effects
that 8q gains may have involve deregulation of SQLE expression.
Chin et al (2007) demonstrated a strong statistical correlation
between chromosomal 8q gains and upregulation of SQLE
expression in human breast cancer, suggesting a direct relation
between gene copy numbers and expression. Even though the
connecting link between SQLE expression and cytogenetic
instability remains unclear, it might be speculated that an increase
in proliferation activity induced by a loop of trace amounts of
cholesterol that is self-sufficient would also increase the likelihood
for genetic aberrations.
We identified mRNA expression of SQLE, located on chromo-
some 8q24.1, to be associated with high-risk ERþ breast cancer
cases. Squalene epoxidase mRNA expression was able to define a
patient subgroup at significantly increased risk of early onset of
metastasis among ERþ stage I/II breast cancer. Furthermore,
SQLE expression remained a significant prognostic factor for
increased/decreased DMFS, independent of established prognostic
factors such as tumour size and grade.
The findings presented here might be used in the future to
identify patients with ERþ breast cancer, which would benefit
from additional treatment besides encdocrine therapy.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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